MedTrace Logo

The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis

NCT05498467 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-05-20

Study results available
· View outcomes & findings →

Summary

The study will investigate if Anakinra can ameliorate allergic contact dermatitis in participants with known nickel allergy

Conditions

  • Allergic Contact Dermatitis

Interventions

DRUG

Anakinra

100 mg Anakinra injections s.c.

DRUG

Sodium Chloride 9mg/ml Injection

9 mg Sodium Chloride injections s.c.

Sponsors & Collaborators

  • Herlev and Gentofte Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-11
Primary Completion
2023-12-01
Completion
2024-08-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05498467 on ClinicalTrials.gov